Literature DB >> 6100425

Elimination kinetics of ceftizoxime in humans with and without renal insufficiency.

M Ohkawa, A Okasho, T Sugata, K Kuroda.   

Abstract

The pharmacokinetics of a single 500-mg intramuscular dose of ceftizoxime were studied in 11 healthy adult volunteers and in 22 patients with various degrees of renal dysfunction. The mean serum half-life of ceftizoxime was 1.44 h in normal subjects and 30.2 h in hemodialysis patients. A significant correlation (P less than 0.001) between the elimination rate constant of ceftizoxime and creatinine clearance was demonstrated. The mean urinary recovery in normal subjects was 75.6% within 6 h of dosage; recovery decreased progressively with reduced renal function.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6100425      PMCID： PMC183730          DOI： 10.1128/AAC.22.2.308

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency.

Authors:  W A Craig; P G Welling; T C Jackson; C M Kunin
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

2.  Drug dosage in patients with renal disease.

Authors:  L C Dettli
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

3.  Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers.

Authors:  S Srinivasan; K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

4.  Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function.

Authors:  J P Fillastre; A Leroy; G Humbert; M Godin
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

5.  Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients.

Authors:  J P Fillastre; A Leroy; M Godin; G Oksenhendler; G Humbert
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

6.  Comparison of antibacterial activity of a new cephalosporin, ceftizoxime (FK 749) with other cephalosporin antibiotics.

Authors:  M Nishida; T Kamimura; N Okada; Y Matsumoto; Y Mine; T Murakawa; S Goto; S Kuwahara
Journal:  J Antibiot (Tokyo)       Date:  1979-12       Impact factor: 2.649

7.  Comparative in vitro activities of cefotaxime and ceftizoxime (FK749): new cephalosporins with exceptional potency.

Authors:  D Greenwood; N Pearson; A Eley; F O'Grady
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

8.  Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

9.  Ceftizoxime (FK 749), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  T Kamimura; Y Matsumoto; N Okada; Y Mine; M Nishida; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

10.  Pharmacokinetics of cefamandole in patients with normal and impaired renal function.

Authors:  H E Mellin; P G Welling; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191
View more
  6 in total

1.  Pharmacokinetics of ceftizoxime.

Authors:  U Gundert-Remy; R Hildebrandt; A Stiehl; P Schlegel
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 2.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 4.  A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime.

Authors:  A Sánchez-Navarro; C I Colino; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R C Heel
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

6.  Metabolism, Excretion, and Pharmacokinetics of [14 C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration.

Authors:  Shiro Miyazaki; Takayuki Katsube; Helen Shen; Charles Tomek; Yukitoshi Narukawa
Journal:  J Clin Pharmacol       Date:  2019-02-07       Impact factor: 3.126
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.